Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16176658rdf:typepubmed:Citationlld:pubmed
pubmed-article:16176658lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:16176658lifeskim:mentionsumls-concept:C0439660lld:lifeskim
pubmed-article:16176658lifeskim:mentionsumls-concept:C1710082lld:lifeskim
pubmed-article:16176658lifeskim:mentionsumls-concept:C1704259lld:lifeskim
pubmed-article:16176658lifeskim:mentionsumls-concept:C1705987lld:lifeskim
pubmed-article:16176658lifeskim:mentionsumls-concept:C0243067lld:lifeskim
pubmed-article:16176658pubmed:issue4lld:pubmed
pubmed-article:16176658pubmed:dateCreated2005-9-22lld:pubmed
pubmed-article:16176658pubmed:abstractTextRecently, three human primary immunodeficiencies associated with impaired TLR signalling were described. Anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID), either X-linked recessive or autosomal dominant, is caused by hypomorphic mutations in NEMO or hypermorphic mutation in IKBA, respectively, both involved in nuclear factor-kappaB (NF-kappaB) activation. These patients present with abnormal development of ectoderm-derived structures and suffer from a broad spectrum of infectious diseases. In vitro studies of the patients' cells showed an impaired, but not abolished, NF-kappaB activation in response to a large set of stimuli, including TLR agonists. More recently, patients with autosomal recessive amorphic mutations in IRAK4 have been reported, presenting no developmental defect and a more restricted spectrum of infectious diseases, mostly caused by pyogenic encapsulated bacteria, principally, but not exclusively Gram-positive. In vitro studies carried out with these patients' cells showed a specific impairment of the Toll-interleukin-1 receptor (TIR)-interleukin-1 receptor associated kinase (IRAK) signalling pathway. NF-kappaB- and mitogen activated protein kinase (MAPK) pathways are impaired in response to all TIR agonists tested. These data, therefore, suggest that TLRs play a critical role in host defence against pyogenic bacteria, but may be dispensable or redundant for immunity to most other infectious agents in humans.lld:pubmed
pubmed-article:16176658pubmed:languageenglld:pubmed
pubmed-article:16176658pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16176658pubmed:citationSubsetIMlld:pubmed
pubmed-article:16176658pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16176658pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16176658pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16176658pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16176658pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16176658pubmed:statusMEDLINElld:pubmed
pubmed-article:16176658pubmed:issn0968-0519lld:pubmed
pubmed-article:16176658pubmed:authorpubmed-author:PicardCapucin...lld:pubmed
pubmed-article:16176658pubmed:authorpubmed-author:CasanovaJean-...lld:pubmed
pubmed-article:16176658pubmed:authorpubmed-author:YangKunKlld:pubmed
pubmed-article:16176658pubmed:authorpubmed-author:von...lld:pubmed
pubmed-article:16176658pubmed:authorpubmed-author:BustamanteJac...lld:pubmed
pubmed-article:16176658pubmed:authorpubmed-author:PuelAnneAlld:pubmed
pubmed-article:16176658pubmed:authorpubmed-author:KuCheng-LungC...lld:pubmed
pubmed-article:16176658pubmed:authorpubmed-author:SantosOrchidé...lld:pubmed
pubmed-article:16176658pubmed:authorpubmed-author:LawrenceTatia...lld:pubmed
pubmed-article:16176658pubmed:authorpubmed-author:ChangHuey-Hsu...lld:pubmed
pubmed-article:16176658pubmed:authorpubmed-author:Al-MousaHamou...lld:pubmed
pubmed-article:16176658pubmed:issnTypePrintlld:pubmed
pubmed-article:16176658pubmed:volume11lld:pubmed
pubmed-article:16176658pubmed:ownerNLMlld:pubmed
pubmed-article:16176658pubmed:authorsCompleteYlld:pubmed
pubmed-article:16176658pubmed:pagination220-4lld:pubmed
pubmed-article:16176658pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16176658pubmed:meshHeadingpubmed-meshheading:16176658...lld:pubmed
pubmed-article:16176658pubmed:meshHeadingpubmed-meshheading:16176658...lld:pubmed
pubmed-article:16176658pubmed:meshHeadingpubmed-meshheading:16176658...lld:pubmed
pubmed-article:16176658pubmed:meshHeadingpubmed-meshheading:16176658...lld:pubmed
pubmed-article:16176658pubmed:meshHeadingpubmed-meshheading:16176658...lld:pubmed
pubmed-article:16176658pubmed:meshHeadingpubmed-meshheading:16176658...lld:pubmed
pubmed-article:16176658pubmed:meshHeadingpubmed-meshheading:16176658...lld:pubmed
pubmed-article:16176658pubmed:meshHeadingpubmed-meshheading:16176658...lld:pubmed
pubmed-article:16176658pubmed:meshHeadingpubmed-meshheading:16176658...lld:pubmed
pubmed-article:16176658pubmed:meshHeadingpubmed-meshheading:16176658...lld:pubmed
pubmed-article:16176658pubmed:meshHeadingpubmed-meshheading:16176658...lld:pubmed
pubmed-article:16176658pubmed:meshHeadingpubmed-meshheading:16176658...lld:pubmed
pubmed-article:16176658pubmed:year2005lld:pubmed
pubmed-article:16176658pubmed:articleTitleHeritable defects of the human TLR signalling pathways.lld:pubmed
pubmed-article:16176658pubmed:affiliationUniversity of Paris-INSERM U550, Necker Medical School, Paris, France. puel@necker.frlld:pubmed
pubmed-article:16176658pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16176658pubmed:publicationTypeReviewlld:pubmed
pubmed-article:16176658pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16176658lld:pubmed